Recent reports have now implicated interleukin 12 and interleukin 23 (IL-12 and IL-23) in the pathophysiology of Crohn’s disease. Indeed, Crohn’s disease patients have overexpression of IL-12 ...

J&J has received US FDA approval for Tremfya (guselkumab), to treat moderately to severely active Crohn's disease (CD) in adults.

Icotrokinra appears to be an effective treatment for adolescents with moderate to severe plaque psoriasis, according to a subgroup analysis of the ICONIC-LEAD study.

This is a developing news story. Please check back soon for updates. Tremfya reduced signs and symptoms of psoriatic ...

US-based pharmaceutical company Johnson & Johnson (J&J) has reported positive results from a Phase IIIb trial of its ...

Johnson & Johnson (J&J) has reported data from the Phase III ICONIC-LEAD trial’s subgroup analysis evaluating icotrokinra in ...

In the Phase III ICONIC-LEAD trial, 75% of adolescents with moderate-to-severe plaque psoriasis treated with icotrokinra ...

Biologics targeting interleukin (IL)-12, IL-23, and IL-17 may have valuable safety benefits among older adults with psoriatic disease, as a lower rate of serious infection was observed among these ...

Biologics targeting interleukin (IL)-12, IL-23, or IL-17 are linked to a 35% lower rate of serious infections in older adults with psoriatic disease compared to other treatments.

Oruka Therapeutics, Inc.’s ORKA share price has dipped by 12.22%, which has investors questioning if this is right time to buy.